bnc-1

BNC-1 is a modulator of amyloid pathology. BNC-1 significantly decreases amyloid burden and improves markers of synaptic integrity in well-established mouse models of amyloid deposition by promoting phosphorylation and activation of Elk-1.

BNC105P是一种基于苯并呋喃的血管破坏剂(VDA)前体化合物，具有潜在的抗血管和抗肿瘤活性。当BNC105P被给药时，这种二钠磷酸酯形式的BNC105迅速转化为BNC105；在活化的内皮细胞中，BNC105与微管蛋白结合并抑制其聚合，这可能导致阻止纺锤体的形成、细胞周期阻滞以及破坏肿瘤的血管结构。随后形成缺氧状态，剥夺肿瘤细胞的营养供应，导致肿瘤细胞凋亡。除了其VDA活性外，BNC105P还通过抑制微管蛋白的聚合直接对肿瘤细胞产生细胞毒作用。值得注意的是，BNC105不是多药耐药P-糖蛋白(Pgp)转运体的底物。

BNC105 是一种微管蛋白聚合抑制剂，具有抗增殖和破坏肿瘤血管的特性。

BNC105P is a benzofuran-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and antineoplastic activities. Upon administration vascular disrupting agent BNC105P, the disodium phosphate ester of BNC105, is rapidly converted to BNC105; in activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may result in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. Hypoxic conditions ensue, depriving tumor cells of nutrients and resulting in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. BNC105 is not a substrate for the multidrug-resistance P-glycoprotein (Pgp) transporter.

Lafuvitug (3BNC-117) 是一种完全人源化的IgG1抗体，专门针对包膜糖蛋白 gp120 蛋白 (gp120) 进行结合。关于 Lafuvitug 的同型对照，请参阅 HumanIgG1kappa, Isotype Control。